EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that it will participate virtually in two upcoming conferences in October:
-
TCR-based Therapies Summit
Title: ARTEMIS® Antibody TCR T Cell Therapies for Solid Tumors
Speaker: Cheng Liu, Ph.D., President and CEO
Date: Tuesday, October 27, 2020
Time: 9:00 a.m. EST
-
Cell & Gene Therapy Bioprocessing & Commercialization
Title: Optimizing Viral Vector Production
Speaker: Nicole Nunez, Ph.D., Process Development Scientist
Date: Thursday, October 22, 2020
Time: 8:00 a.m. EST
ABOUT EUREKA THERAPEUTICS, INC.
Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. ET140203, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.